NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ:CLDA), a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, today announced that its PGxHealth™ division has achieved significant growth in positive reimbursement policies for its FAMILION® genetic test for Long QT Syndrome (LQTS).
